股票里什么叫爆仓LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
March 13, 2020 - 3:30 p.m.
股票里什么叫爆仓The LabCorp 2019 Novel Coronavirus (COVID-19), NAA test is available for ordering by physicians or other authorized healthcare providers anywhere in the U.S.
LabCorp continues to perform its 2019 Novel Coronavirus (COVID-19) test and to increase test capacity for patients who should be tested. We are working closely with the CDC, FDA and others on a swift response to address this public health crisis. Our team is proud to play an important role as part of an industry consortium that is working every day to meet the growing demand for national testing. Our utmost concern is for the safety of the public, patients, healthcare service providers, and our employees.
on Thursday, March 5, and began receiving specimens in the lab the next day, with more coming since then. We are testing specimens and reporting results to the ordering clinicians and to public health authorities as may be required. LabCorp is now able to perform several thousand tests per day and is rapidly adding new equipment and staff to create additional capacity. We continue reviewing all opportunities to expand testing at LabCorp lab facilities across the country.
股票里什么叫爆仓LabCorp’s test detects the presence of the underlying virus that causes COVID-19 and is for use with patients who meet guidance for testing.
股票里什么叫爆仓At this time, the test can be ordered anywhere in the U.S. by physicians or other healthcare providers.
Patients for whom testing has been ordered should not be sent to a LabCorp location to have a specimen collected. The specimen must be collected by the ordering clinician and then be sent to LabCorp using standard procedures.股票里什么叫爆仓 The turnaround time to provide test results is typically three to four days from the pickup of the specimen to release of the test result.
Please refer to the guidance below for more specific information about the test, test methodology, appropriate specimen types, specimen packaging and shipping, and test result reporting.
Important Information for Patients and Healthcare Providers related to testing for COVID-19:
Yes. Physicians and other authorized healthcare providers can order the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test the same way that other tests are ordered from LabCorp. Information about the test, including instructions for specimen collection and preparation, is available here.
Reporting should take up to 3-4 days from the pickup of the specimen to release of the test result. After the specimen is received at the lab, it takes approximately 24 hours to complete the testing process. The time to complete testing is generally the same for any lab that is performing testing for COVID-19 using RT-PCR technology.
Test results are most typically reported electronically, which generally allows for faster delivery. Due to the need for rapid response, positive results are being reported to the ordering provider by telephone. LabCorp is also reporting test results to public health authorities, as may be required. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests.
Yes, in addition to its test for COVID-19, LabCorp is also able to perform the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel if needed to meet testing demand. The CDC test is for the presumptive detection of 2019-nCoV RNA in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate), and other authorized specimens collected from individuals who meet CDC criteria for COVID-19 testing. Please for more information.
The symptoms can include a cough, possibly with a fever and shortness of breath. There are some early reports of non-respiratory symptoms, such as nausea, vomiting, or diarrhea. Most people recover within a few days. However, some people — especially the elderly or people who have a weakened immune system — may develop a more serious infection, such as bronchitis or pneumonia.
In addition to the standard infection control precautions that we follow on a daily basis, LabCorp has taken a number of additional steps to help protect its employees, patients and business. In summary, we have provided information and training to the LabCorp Diagnostics teams, who may need to manage patients and specimens differently during this time. This includes providing specific information for staff at and visitors to our patient service centers (PSCs).
We have provided employees with updated information about travel restrictions and best practices for minimizing the risk of exposure generally and during any travel that is taken. For our Covance Drug Development business, which has significant employees and operations around the globe, response teams are taking steps to manage through changing business requirements.
Current guidance does not support the general use of masks or other personal protective equipment by the public. Patients who meet established criteria will be offered a face mask to help minimize the risk of spreading airborne diseases. The best methods to limit the risk of exposure or spreading the virus are everyday preventative actions as . Hand sanitizer is available at all of our locations, and we encourage its use by all visitors.
股票里什么叫爆仓LabCorp is taking reasonable precautions during the ongoing COVID-19 outbreak to help maintain business and operational continuity. We are in close contact with our key suppliers and vendors, and we have resiliency plans to help us address impact on our supply chain or logistics. We will provide more information as necessary in the event of any supply chain or logistics issues that may affect patients or customers.
股票里什么叫爆仓Please visit this page regularly to obtain the most-current information from LabCorp. We will update this website as new information becomes available.